Skip to main content
. Author manuscript; available in PMC: 2023 Sep 2.
Published in final edited form as: Mol Cancer Ther. 2023 Mar 2;22(3):371–380. doi: 10.1158/1535-7163.MCT-22-0515

Figure 2. αCD133/αCD3 and αEpCAM/αCD3 CSAN labeled T-cells selectively activate and kill target CD133+ and EpCAM+ cells, respectively.

Figure 2.

Target HT-29 cell (CD133highEpCAMhigh colon carcinoma) lysis, by unactivated PBMCs, was evaluated at a set 10:1 E:T ratio with increasing concentrations of (A) αCD133/αCD3 CSANs, (B) αEpCAM/αCD3 CSANs or (C) both αCD133/αCD3 CSANs and αEpCAM/αCD3 CSANs in combination. Target MDA-MB-231 cell (CD133lowEpCAMlow TNBC cells) lysis, by unactivated PBMCs, was evaluated at a set 10:1 E:T ratio with increasing concentrations of (D) αCD133/αCD3 CSANs and (E) αEpCAM/αCD3 CSANs, as well as in (F) combination. When treated in combination, both αCD133/αCD3 CSANs and αEpCAM/αCD3 CSANs were used at a 1:1 ratio. CSAN controls were generated by combining a targeted DHFR2 with a non-targeted DHFR2 (1DD). Data shown was obtained from one donor (n=3), but representative of three donors. *P<0.05 with respect to targeted CSAN therapy and non-targeted CD3 control, by 2-tailed Student’s t test.